| Market Cap | 18.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -58.92M |
| Shares Out | 12.81M |
| EPS (ttm) | -14.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 67,544 |
| Open | 1.430 |
| Previous Close | 1.390 |
| Day's Range | 1.410 - 1.480 |
| 52-Week Range | 1.250 - 145.460 |
| Beta | 19,964.30 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 30, 2025 |
About PPCB
Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the research activities for the POP1 Program and the Un... [Read more]
Financial Performance
Financial StatementsNews
CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
This accelerates development of our clinical pipeline and leverages Hexstone's previous investments in companies that have built digital asset treasuries.
Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital
This accelerates development of our clinical pipeline and leverages Hexstone's previous investments in companies that have built digital asset treasuries.
Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy
Propanc announced its fiscal year-end following the filing of its annual 10-K report with the Securities and Exchange Commission on September 29, 2025.
Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office
MELBOURNE, Australia, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patient...
Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum
Purchase of Ethereum will enhance a multi-faceted corporate strategy of cryptocurrency exposure, pharmaceutical drug development and asset acquisition.
Propanc Biopharma Provides Shareholder Update
Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study
Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ
MELBOURNE, Australia, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients...
U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer
Eight issuers listed in the US this past week, six of which were eligible for inclusion in our IPO stats, joined by two SPACs. There are no IPOs currently scheduled for the week ahead, though some sma...
Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering
MELBOURNE, Australia, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patien...